There are currently 68 clinical trials in Arlington, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Clinical Research Institute, Texas Clinical Research Institute, LLC, Texas Retina Associates and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults with Depression
NCT05966532
Recruiting
This is a cross-sectional pilot study designed to establish hot and cold cognitive functions and underlying neurocircuitry in older adults with MDD. The investigators will study 120 participants aged 21-80 years old with MDD. All participants will undergo clinical and neurocognitive assessment, and Magnetoencephalography (MEG)/Magnetic resonance imaging (MRI) procedures at one time point. The investigators will also enroll 120 demographically matched comparable, never-depressed healthy participa... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
01/08/2025
Locations: University of Texas Arlington, Arlington, Texas
Conditions: Major Depressive Disorder (MDD), Healthy Adult Volunteer
Register for Updates
Know and Own Your Movement-related Metrics Via Wearable Devices
NCT05490641
Recruiting
This study aims to promote daily physical activity in cancer survivors who are at high risk for type 2 diabetes (T2D) by using a personalized biological-based feedback strategy. T2D is one of the most common co-occurring conditions in cancer survivors and can worsen cancer-related health outcomes, especially in those who are insufficiently active. The investigators hypothesize that seeing the immediate impacts of exercise on their biological status will motivate cancer survivors to exercise. The... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: The University of Texas at Arlington, Arlington, Texas
Conditions: Cancer, Survivorship
Register for Updates
RESTORE: An RCT to Evaluate the Efficacy of the Revi System
NCT06217328
Recruiting
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/11/2024
Locations: Urology Partners of North Texas, Arlington, Texas
Conditions: Urinary Urge Incontinence
Register for Updates
Exploring Virtual Reality Adventure Training Exergaming
NCT05563805
Recruiting
The current project aims to design and implement an 8-week Virtual Reality Adventure Therapy Exergaming (V-RATE) intervention focused on women veterans. A randomized controlled trial using a repeated measure design with a 1-month follow-up assessment will be employed to examine effects on physical and mental health outcomes.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
10/23/2024
Locations: University of Texas at Arlington, Arlington, Texas
Conditions: Physical Activity, Sedentary Behavior, Depression, Cognitive Function, Post Traumatic Stress Disorder, Quality of Life, Anxiety
Register for Updates
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835
Recruiting
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Z... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/12/2024
Locations: Liberty Research Center, Arlington, Texas +1 locations
Conditions: Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Register for Updates
A Phase 3B Study to Evaluate Bone Mineral Density with Long-Term Use of Relugolix Combination Tablet in Women with Uterine Fibroids or Endometriosis
NCT05862272
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
09/24/2024
Locations: Arlington, Arlington, Texas
Conditions: Uterine Fibroids, Endometriosis
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Local Institution - 001-888-B, Arlington, Texas +1 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
ABTECT - Maintenance
NCT05535946
Recruiting
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhi... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/06/2024
Locations: Texas Clinical Research Institute, LLC, Arlington, Texas
Conditions: Ulcerative Colitis
Register for Updates
Brain Vascular and Neurocognitive Health
NCT06497413
Recruiting
The overall research objective of this proposal is to determine the acute and chronic impact of transcranial photobiomodulation on indices of cerebral vascular health and neurocognitive function.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/29/2024
Locations: UT Arlington - Science and Engineering Innovation and Research Building, Arlington, Texas
Conditions: Cognitive Decline, Cognitive Dysfunction, Alzheimer Disease, Vascular Disease, Peripheral
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Texas Clinical Research Institute, LLC, Arlington, Texas
Conditions: Ulcerative Colitis
Register for Updates
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
NCT06425549
Recruiting
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/25/2024
Locations: Ps0021 50201, Arlington, Texas
Conditions: Moderate to Severe Plaque Psoriasis
Register for Updates
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
NCT03471117
Recruiting
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatme... Read More
Gender:
ALL
Ages:
Between 35 years and 70 years
Trial Updated:
05/22/2024
Locations: University of Texas at Arlington, Arlington, Texas
Conditions: Chronic Kidney Diseases
Register for Updates